Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 281

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1B
Chunk 281
---
 amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

    Name
     
    Title
     
    Date

    /s/ Jeremy Bender, Ph.D., M.B.A.
     
    Chief Executive Officer and President (Principal Executive Officer)
     
    February 25, 2025

    Jeremy Bender, Ph.D., M.B.A.

    /s/ Charles N. York II, M.B.A.
     
    Chief Operating Officer and Chief Financial Officer(Principal Financial and Accounting Officer)
     
    February 25, 2025

    Charles N. York II, M.B.A.

    /s/ Garry Nicholson, M.B.A.
     
    Chair and Director
     
    February 25, 2025

    Garry Nicholson

    /s/ Habib Dable
     
    Director
     
    February 25, 2025

    Habib Dable

    /s/ Scott Garland
     
    Director
     
    February 25, 2025

    Scott Garland

    /s/ Michael Gladstone
     
    Director
     
    February 25, 2025

    Michael Gladstone

    /s/ William Grossman, M.D., Ph.D.
     
    Director
     
    February 25, 2025

    William Grossman, M.D., Ph.D.

    /s/ Natalie Holles
     
    Director
     
    February 25, 2025

    Natalie Holles

    /s/ John A. Josey, Ph.D., M.B.A.
     
    Director
     
    February 25, 2025

    John A. Josey, Ph.D., M.B.A.

    /s/ Saira Ramasastry, M.S., M.Phil.
     
    Director
     
    February 25, 2025

    Saira Ramasastry, M.S., M.Phil.

133

INDEX TO FINANCIAL STATEMENTS

    Report of Independent Registered Public Accounting Firm (PCAOB ID: 238)
    F-2

    Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)
    F-5

    Balance Sheets
    F-6

    Statements of Operations
    F-7

    Statements of Comprehensive Loss
    F-8

    Statements of Stockholders’ Equity
    F-9

    Statements of Cash